ArticleMaterials today. Bio2025
Monometal-doped nanozymes ameliorate rheumatoid arthritis by regulating neutrophil ferroptosis via the MDM2-P53-SLC7A11 pathway.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanozyme-Mediated Joint Homeostasis Restoration: Emerging Strategies for Arthritis Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent joint inflammation and swelling. Neutrophils play pivotal roles in the pathogenesis of RA and represent potential therapeutic targets. In this study, we investigated the efficacy of monometal-doped nanozymes (MDNs)on the RA murine model and the therapeutic mechanisms. Our results demonstrated that these MDNs effectively inhibit the formation of neutrophil extracellular traps (NETs) and suppress inflammatory responses. Furthermore, the MDNs induce ferroptosis in neutrophils by regulating the MDM2-P53-solute carrier family 7 member 11 (SLC7A11) signaling pathway. Collectively, these findings suggest that MDNs may serve as a promising therapeutic strategy for RA by modulating the ferroptosis-NETosis balance in neutrophils via the MDM2-p53-SLC7A11 axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.